Published on 24 January 2023
Description:
A warm welcome to the first PharmaTimes of the year. Our cover story focuses on one of the biggest questions in industry – are we really getting closer to customers? We also look at the future acceleration of R&D, but also the challenge of reducing wider inequalities throughout this sector.
Categories:
PharmaTimes27 articles from this collection:
Cover
2 - FlyPharma Middle East
3 - From the editor
This month PharmaTimes presents Alantra’s annual ranking of the fastest growing pharma companies in the UK, and again there is much cause for celebration. As the analysis shows, a relentless focus on innovation and a determination to solve problems hindering patient outcomes are key traits that have helped those at the top shine in a sector that saw average growth of 33% in 2020.
4-5 - Contents
6 - NEWS: Treatments
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on the potential reclassification of two progestogen-only, oral contraceptive pills containing desogestrel: Lovima 75mcg and Hana 75mcg film-coated tablets.
7 - NEWS: Clinical Trials
8 - NEWS: Collaboration
9 - NEWS: Conditions
10-12 - COVER STORY: Close encounters
13 - OXFORD PHARMAGENESIS: Follow me, follow you
14-15 - CLINICAL TRIALS: Trial blazing
16-17 - EQUITY: Some more equal than others
18-19 - PATIENT EXPERIENCE: Inspiring hope
20-21 - PHARMA: Human after all
22 - COMMUNIQUE AWARDS 2023
23 - INNOVATION: Yes brainer
24-25 - FUTURE: Data day
26 - AI: Good Vibes Only
27-29 - NHS: Crystal clear?
30-31 - FLYPHARMA: FlyPharma debuts in the Middle East
32 - ACCESS: Masters of the pharmaverse
33 - Adverts
34-35 - TECH: Reliable printer?
36-37 - Your moves
38 - INTCROY
39 - PHARMAFILE
40 - FlyPharma Europe
PharmaTimes
PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.